Antimullerian hormone and obesity: insights in oral contraceptive users

Anne Z. Steiner, Frank Z. Stanczyk, Stan Patel, Alison Edelman

Research output: Contribution to journalArticlepeer-review

93 Scopus citations


Background: The study was conducted to examine the impact of oral contraceptives (OCs) on serum antimullerian hormone (AMH) levels by obesity status in reproductive-age women. Study Design: Ovulatory women, ages 18-35 years, of normal (<25 kg/m2; n=10) and obese (>30 kg/m2; n=10) body mass index (BMI) received a low-dose OC (20 mcg ethinyl estradiol/100 mcg levonorgestrel) for two cycles. Serum samples obtained at several time points during active pill use and hormone-free intervals were analyzed for AMH, follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol and inhibin B. Results: AMH levels did not differ by OC cycle day in either BMI group. On average, AMH levels were 34% lower in the obese group (2.9±2.1 vs. 4.4±1.8 ng/mL, p<.05). Modeling to determine differences in AMH throughout the cycle based on obesity status demonstrated significantly lower levels (p<.05), whereas serum AMH, FSH, LH, estradiol and inhibin B levels revealed no correlations when all time points were included. Conclusions: In reproductive-age women, serum AMH levels do not appear to fluctuate during OC use, but AMH levels are significantly lower in obese women. Lower levels do not appear to be due to differences in gonadotropin levels or ovarian activity.

Original languageEnglish (US)
Pages (from-to)245-248
Number of pages4
Issue number3
StatePublished - Mar 2010


  • Antimullerian hormone
  • Obesity
  • Oral contraceptives

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology


Dive into the research topics of 'Antimullerian hormone and obesity: insights in oral contraceptive users'. Together they form a unique fingerprint.

Cite this